Ajuste direto para aquisição de RISPERIDONA [100 MG/0.490 ML; PÓ SUSP INJ LP; SERINGA] e RISPERIDONA [75 MG/0.383 ML; PÓ SUSP INJ LP; SERINGA]

ID 12572817 · Portal BASE
Price
Base Price
€597,008 .00
Effective Price
€2,445 .00 -99.6%
Contract Details
Contract Type
Aquisição de bens móveis
Procedure
Ajuste Direto Regime Geral
CPV Code
33600000
Location
Portugal, Braganca
Bidder Count
—
Winner
LAB. FARMACEUTICOS ROVI, SA.
NIF 980166705
Company
Dates
Publication
15 Jan 2026
Celebration
08 Jan 2026
Contracting Entity
Unidade Local de Saúde do Nordeste, E. P. E.
NIF 509932584
Public body
Data Source
Portal BASE
Api · synced 2026-04-17
Risk Flags
Score 60 · MEDIUM RISK
A1 · Repeat Direct Award
A1_REPEAT_DIRECT_AWARD
HIGH
Authority
449
Supplier
253
Number of Awards
4
Rule
A1 repeat direct award: 4 awards within 36 months
Detected 2026-03-06
A9 · Abnormal Price Reduction
A9_PRICE_REDUCTION
LOW
Base price
597008.0
Total effective price
2445.0
Ratio
0.0041
Direction
reduction
Rule
A9 price reduction: ratio 0.0041 outside [0.5, 1.5]
Detected 2026-03-06